Stock Scorecard

Stock Summary for Biohaven Ltd (BHVN) - $15.71 as of 8/18/2025 12:16:53 PM EST

Total Score

6 out of 30

Safety Score

28 out of 100

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for BHVN

Positive Quarterly and Annual earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the Annual earnings growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for BHVN

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for BHVN

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for BHVN

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for BHVN (28 out of 100)

Stock Price Rating (Max of 10) 6
Historical Stock Price Rating (Max of 10) 1
Stock Price Trend (Max of 10) 0
Book Value (Max of 10) 2
Book Value to Price (Max of 10) 0
Analyst Buy Ratings (Max of 5) 5
Analyst Strong Buy Ratings (Max of 5) 4
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 0
Trading Volume (Max of 10) 10
Price to Earnings (Max of 10) 0
Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) 0

Latest News for for BHVN

Faruqi & Faruqi Reminds Biohaven Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of August 12, 2025 - BHVN 8/17/2025 11:15:00 AM
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Biohaven Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action - BHVN - Biohaven ( NYSE:BHVN ) 8/15/2025 6:18:00 PM
DEADLINE ALERT for BHVN and NEOG: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders - Biohaven ( NYSE:BHVN ) , Neogen ( NASDAQ:NEOG ) 8/13/2025 4:12:00 PM
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biohaven - Biohaven ( NYSE:BHVN ) 8/12/2025 4:36:00 PM
Biohaven Ltd. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before September 12, 2025 to Discuss Your Rights - BHVN - Biohaven ( NYSE:BHVN ) 8/11/2025 8:25:00 PM
2 Beaten-Down Stocks to Buy and Hold 8/10/2025 1:15:00 PM
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Biohaven Ltd. ( BHVN ) Shareholders - Biohaven ( NYSE:BHVN ) 8/8/2025 8:15:00 PM
DEADLINE ALERT for HIMS, IRBT, CNC, BHVN: Law Offices of Howard G. Smith Reminds Investors of Opportunity to Lead Securities Fraud Class Actions - Biohaven ( NYSE:BHVN ) , Centene ( NYSE:CNC ) 8/8/2025 5:51:00 PM
Deadline Alert: Biohaven Ltd. ( BHVN ) Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit - Biohaven ( NYSE:BHVN ) 8/7/2025 5:19:00 PM
BHVN INVESTORS: Kirby McInerney LLP Reminds Biohaven Ltd. Investors of Important Deadline and Encourages Investors to Contact the Firm - Biohaven ( NYSE:BHVN ) 8/6/2025 10:00:00 PM

Financial Details for BHVN

Company Overview
Ticker BHVN
Company Name Biohaven Ltd
Country USA
Description Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops candidate products targeting neurological diseases and rare disorders in the United States. The company is headquartered in New Haven, Connecticut.
Sector Name LIFE SCIENCES
Industry Name PHARMACEUTICAL PREPARATIONS
Most Recent Quarter 6/30/2025
Next Earnings Date N/A

Stock Price History
Last Day Price 15.71
Price 4 Years Ago 0.00
Last Day Price Updated 8/18/2025 12:16:53 PM EST
Last Day Volume 2,814,846
Average Daily Volume 1,926,000
52-Week High 55.70
52-Week Low 12.79
Last Price to 52 Week Low 22.83%

Valuation Measures
Trailing PE N/A
Industry PE 43.35
Sector PE 59.06
5-Year Average PE -4.08
Free Cash Flow Ratio 10.01
Industry Free Cash Flow Ratio 15.81
Sector Free Cash Flow Ratio 30.26
Current Ratio Most Recent Quarter 3.82
Total Cash Per Share 1.57
Book Value Per Share Most Recent Quarter 1.27
Price to Book Ratio 11.19
Industry Price to Book Ratio 31.11
Sector Price to Book Ratio 26.93
Price to Sales Ratio Twelve Trailing Months 0.00
Industry Price to Sales Ratio Twelve Trailing Months 34.46
Sector Price to Sales Ratio Twelve Trailing Months 15.21
Analyst Buy Ratings 11
Analyst Strong Buy Ratings 4

Share Statistics
Total Shares Outstanding 105,788,000
Market Capitalization 1,661,929,480
Institutional Ownership 84.93%

Dividends
Ex-Dividend Date N/A
Previous Dividend Amount 0.0000
Current Dividend Amount 0.0000
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement
Quarterly Earnings Growth YOY 0.00%
Annual Earnings Growth -107.37%
Reported EPS 12 Trailing Months -7.46
Reported EPS Past Year -3.80
Reported EPS Prior Year -9.15
Net Income Twelve Trailing Months -766,971,000
Net Income Past Year -846,422,000
Net Income Prior Year -408,168,000
Quarterly Revenue Growth YOY 0.00%
5-Year Revenue Growth -18.96%
Operating Margin Twelve Trailing Months 0.00%

Balance Sheet
Total Cash Most Recent Quarter 165,797,000
Total Cash Past Year 99,134,000
Total Cash Prior Year 248,402,000
Net Cash Position Most Recent Quarter -91,273,000
Net Cash Position Past Year -527,586,000
Long Term Debt Past Year 626,720,000
Long Term Debt Prior Year 626,720,000
Total Debt Most Recent Quarter 257,070,000
Equity to Debt Ratio Past Year 0.40
Equity to Debt Ratio Most Recent Quarter 0.34
Total Stockholder Equity Past Year 423,436,000
Total Stockholder Equity Prior Year 427,975,000
Total Stockholder Equity Most Recent Quarter 134,587,000

Free Cash Flow
Free Cash Flow Twelve Trailing Months -646,432,000
Free Cash Flow Per Share Twelve Trailing Months -6.11
Free Cash Flow Past Year -586,502,000
Free Cash Flow Prior Year -334,773,000

Options
Put/Call Ratio 0.32
Has Options Options Chain
Liquidity Rating

Technical Analysis
Yahoo Finance Chart Yahoo Finance Chart
MACD -0.11
MACD Signal -0.10
20-Day Bollinger Lower Band 11.10
20-Day Bollinger Middle Band 16.34
20-Day Bollinger Upper Band 21.58
Beta 3.50
RSI 47.71
50-Day SMA 31.65
150-Day SMA 29.01
200-Day SMA 0.00

System
Modified 8/15/2025 6:54:52 PM EST